secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001770787-24-000058
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics reports Q2 revenue $153.1M (+4% YoY), guides FY24 down to $640-660M; CFO resigns, Taich appointed
--------------------------------------------------------------------------------

- Q2 revenue $153.1M, +4% YoY; net loss $37.9M vs $62.4M loss in prior year.
- Operating expenses down 10% to $146.0M; gross margin flat at 68%.
- Full year 2024 revenue guidance lowered to $640-660M from $670-690M (3-7% growth).
- CFO Justin McAnear resigns effective Aug 30; Adam Taich appointed CFO effective Aug 12.
- Mennah Moustafa named Chief Commercial Officer effective Aug 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078724000058/0001770787-24-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078724000058/txg-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001770787-24-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer